Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Company Drug

BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment

Fineline Cube May 13, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Medical Device

United Imaging Healthcare Gains FDA Approval for uAngio AVIVA Interventional X-ray System

Fineline Cube May 13, 2025

China-based United Imaging Healthcare (UIH, SHA: 688271) announced that it has received marketing approval from...

Policy / Regulatory

Trump Executive Order Seeks to Align US Prescription Drug Prices with Global Standards

Fineline Cube May 13, 2025

U.S. President Donald J. Trump has signed an executive order aimed at aligning prescription drug...

Company Drug

Fosun Pharma’s FCN-159 Granted Breakthrough Therapy Designation for Pediatric LCH

Fineline Cube May 13, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its novel small-molecule...

Company Drug

Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections

Fineline Cube May 13, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...

Company Deals

Roche Invests $550 Million in Indianapolis Diagnostics Facility for CGM Systems

Fineline Cube May 13, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced plans to invest up to USD 550...

Company Drug

RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints

Fineline Cube May 13, 2025

China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...

Company Deals

Eastenova Biotechnology Makes Hong Kong IPO Debut With Regenerative Medicine Focus

Fineline Cube May 13, 2025

China-based Eastenova (Chengdu) Biotechnology Co., Ltd. this week made an initial public offering (IPO) to...

Company Drug

AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD

Fineline Cube May 13, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...

Company Drug

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Fineline Cube May 13, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

Fineline Cube May 12, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...

Company Medical Device

MicroPort’s Talos Stent Gains Marketing Approval in Argentina

Fineline Cube May 12, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Policy / Regulatory

Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality

Fineline Cube May 12, 2025

The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...

Company Deals

Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development

Fineline Cube May 12, 2025

China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....

Company Deals

EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products

Fineline Cube May 12, 2025

China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...

Company Drug

Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment

Fineline Cube May 12, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...

Company Deals

Eli Lilly and Purdue Expand Partnership With $250 Million Investment

Fineline Cube May 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...

Posts pagination

1 … 180 181 182 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.